Abstract
Genetic testing rates, practices and trends for ovarian cancer patients in the PARP inhibitor era (2158)
Full Text
Sign-in/Register to access full text options
Published version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have